States such as New York, Massachusetts, Pennsylvania, California, and Illinois, will begin selling Mifepristone in Walgreens pharmacies in select locations this month. Last year the FDA decision allowed retail pharmacies to sell Mifepristone, a drug accounting for more than half of U.S. abortions, in the country for the first time. If the Supreme Court decides to follow the lower court’s lead and roll back the FDA’s distribution rules, distribution by pharmacies will be heavily impacted and abortion care increasingly more inaccessible.
“They would have to stop dispensing it and revert back to FDA’s previous regulations that only allowed patients to receive mifepristone from the clinic where it was prescribed,”
Katie Kraschel, a Northeastern University law professor specializing in health policy.
